By Anna Edney
May 5, 2020, 4:28 PM EDT
... as quickly as pharmacies were drained of the pills, the tide has now turned against hydroxychloroquine and its chemical cousin, chloroquine. Regulators and scientists have raised concerns about potentially serious side effects, while Gilead Sciences Inc.s antiviral therapy remdesivir was cleared for U.S. use. Some hospitals, including Mount Sinai Health System in New York, no longer include the drug in their treatment regimen for Covid-19.
The surge resulted in shortages that left patients whod long taken the medication to treat lupus and rheumatoid arthritis hunting for alternatives. To help get more drugs to market, the Food and Drug Administration has allowed overseas manufacturing facilities that were previously sanctioned for quality violations to begin producing it for U.S. patients.
Hydroxychloroquine prescriptions jumped to 298,660 during the week of March 20, more than doubling from a week earlier, according to data compiled by Bloomberg Intelligence. But prescriptions have now plummeted back to nearly normal levels, and there are signs a speed-up in manufacturing is slowing ...
https://www.bloomberg.com/news/articles/2020-05-05/trump-s-virus-drug-whim-costs-millions-even-as-the-mania-wanes